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ABSTRACT
We evaluated the benefit of tailoring treatments for a colorectal adenocarcinoma 
cancer cohort according to tumor molecular profiles, by analyzing data collected on 
patient responses to treatments that were guided by a tumor profiling technology 
from Caris Life Sciences. DNA sequencing and immunohistochemistry were the 
main tests that predictions were based upon, but also fragment analysis, and in situ 
hybridization. The status of the IHC biomarker for the thymidylate synthase receptor 
was a good indicator for future survival. Data collected for the clinical treatments of 
95 colorectal adenocarcinoma patients was retrospectively divided into two groups: 
the first group was given drugs that always matched recommended treatments as 
suggested by the tumor molecular profiling service; the second group received at least 
one drug after profiling that was predicted to lack benefit. In the matched treatment 
group, 19% of patients were deceased at the end of monitoring compared to 49% in 
the unmatched group, indicating a benefit in mortality by tumor molecular profiling 
colorectal adenocarcinoma patients.
INTRODUCTION
Colorectal cancer (CRC) is the third most prevalent 
cancer globally. Over a million cases are diagnosed each year 
and there are almost 700,000 deaths due to it annually [1–3]. 
It occurs more in developed countries [4, 5], with the highest 
rates in Australia, New Zealand, Europe and the USA. 
CRC risk is strongly related to age and sex, and 
is most common in men and older people. Only a small 
proportion of colorectal cancers are thought to be due 
to inherited genetic abnormalities, while lifestyle factors 
such as diet, obesity, smoking, and lack of physical 
activity are much more influential. In about 20% of 
all cases there is a family history of colon cancer, and 
around 4% are due to the inherited genetic disorders 
familial adenomatous polyposis (FAP) and hereditary 
non-polyposis colon cancer (HNPCC) [4]. 
The acquisition of somatic mutations in oncogenes 
such as KRAS, RAF, and PI3K are often seen in colon 
cancer. Upregulation of the WNT and TGF-β signaling 
pathways results in increased activity of MYC, an 
important effector of colorectal cancer [6]. However, 
epigenetic changes are more frequent in colon cancer 
than mutations in genes; often a colon tumor has only 
one or two oncogene driver mutations, one to five tumor 
suppressor driver mutations, with around sixty passenger 
mutations, while there are hundreds of epigenetic changes. 
CpG island methylation of the DNA sequences encoding 
miR-34b/c, miR-124a, miR-137 and miR-342 resulting 
in their reduced expression can affect expression of 
hundreds of target genes in each case and are associated 
with colorectal cancer [7, 8, 9]. Hypermethylation or 
hypomethylation of CpG islands and changes in histones 
and chromosomal architecture are other (epigenetic) changes 
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that can cause colorectal cancers. The development of 
clinical sequencing has enabled pre-treatment sequencing 
of relevant MAPK pathway genes such as KRAS, BRAF 
and MEK1, that predict response to EGFR targeted 
therapies such as cetuximab and panitumumab [10].
Guiding treatments using characterization of tumor 
biomarkers such as immunohistochemistry and genomic 
sequencing across many cancer types has resulted in better 
outcomes [11, 12]. We looked at the efficacy of one such 
method (outside the context of clinical KRAS and BRAF 
sequencing) from Caris Life Sciences, for colorectal 
adenocarcinomas. The effect of this profiling approach on 
overall survival and drug use was assessed.
RESULTS
Patient characteristics
Data describing advanced colorectal adenocarcinoma 
patients who underwent treatment was divided into 
two groups depending upon if treatments matched 
recommendations that used tumor molecular profiles. 
In the matched group, 42 patients received at least one 
recommended drug subsequent to collection for profiling 
and none that were not. In the unmatched group 53 patients 
all received one or more drugs predicted by profiling to lack 
benefit after sample collection. Patients and their tumors are 
summarized in Table 1.
Treatment analysis
Waterfall plots showing drugs received and 
survival for both treatment groups are shown in Figure 
1. The clinical information for the 42 matched and 53 
unmatched patients are depicted as columns (on the left 
and right of the figure respectively), where green shows 
administration of drugs expected to be of benefit, red is 
drugs that lack benefit, and yellow is both of these types 
in combination.
The drugs that were given are shown in Table 2. 
The number of patients that received a particular drug is 
shown in the first column, and the number of continuous 
treatment periods of a drug is shown in all other columns, 
i.e. treatments of the same patient with an intervening 
time are counted separately. The drugs given to the 
most number of patients were fluorouracil (87 patients), 
oxaliplatin (81), leucovorin calcium (77), bevacizumab 
(52) and irinotecan hydrochloride (47).
Patients received 6.63 treatments on average; 38% 
were profiled to be beneficial, 17% had no benefit, and 
45% were neither of these. Matched patients had 4.17 
treatments on average; 53% of these were predicted 
of benefit, 0% no benefit, and 47% neither. Unmatched 
patients had an average of 8.58 drug treatments; 33% of 
which were of benefit, 23% lacked benefit and 44% neither 
of these. 8% of unmatched patients had one or more drug 
treatments of benefit, and 7% had at least two of these 
types of treatment. Before profiling, patients received 3.92 
lines of treatment on average.
The drugs that were profiled as beneficial that were 
most often given were fluorouracil (115 treatments), 
oxaliplatin (46), bevacizumab (33), irinotecan hydrochloride 
(21), and capecitabine (14). The drugs lacking benefit 
that were most commonly prescribed were irinotecan 
hydrochloride (34 times), oxaliplatin (28), fluorouracil (25), 
and cetuximab (9).
Some of the drugs did not have a recommendation, 
and this neither category constituted 47% of treatments in 
the matched group and 44% in the unmatched cohort. Of 
this type, leucovorin calcium was given most often - 120 
times, which was 19% of all treatments.
Fluorouracil was given far more often when it 
was profiled to be of benefit - 115 times that it was 
given coincided with beneficial predictions, whereas 25 
did not. Oxaliplatin was given for 46 periods of time 
when predicted to be useful, whereas 28 treatments 
were expected to lack benefit, and 26 neither. Irinotecan 
hydrochloride was less optimal in its use, with 21 
beneficial treatments, 34 lacking benefit, and two being 
of neither type. Interestingly, given the reliance on 5FU 
related compounds in the systemic treatment of CRC, we 
found that thymidylate synthase (TS) was a marker for 
worse outcomes in CRC (Figure 2). The literature already 
documents worse outcomes with high levels of TS [13]. 
However, only patients with unmatched treatments had 
positive biomarker results when IHC testing for TS.
Mismatch repair (MMR) deficient cancers are 
targets for anti-PD-1 therapy [14], and recently the FDA 
has approved Keytruda (pembrolizumab) for unresectable 
or metastatic solid tumors that have been identified as 
having a biomarker for MSI-H (microsatellite instability-
high) or MMR deficient. We observe that although only 
three patients in this cohort had IHC markers tested for 
PD-L1 and the mismatch repair related markers MSH2, 
MSH6, PMS2 and MLH1; in all cases PD-L1 was negative 
while all of the MMR markers were positive.
Survival analysis
In the matched group 19% of patients were deceased 
by the end of monitoring, and 49% of the unmatched 
group (P = 0.0022). The matched group survived for 
442 days on average and the unmatched survived for 541 
days (P = 0.1773) after profiling. A Kaplan-Meier curve 
in Figure 3 (top-right) shows the overall survival for 
matched patients and unmatched patients. There is also a 
survival plot in Figure 3 (mid-right). The matched group 
have a lower mortality, but survive on average for less 
time after profiling when measuring up to the last time 
of monitoring. However, it can be seen that the matched 
group shown on the left of Figure 1 have been monitored 
for less time overall; the matched group’s average number 
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of contact days after diagnosis is 733, and the unmatched 
group’s is 1150 days. This may explain why in this cohort 
mortality is lower for matched treatments while time that 
patients are known to have survived is lower.
Biomarker values are compared between matched 
and unmatched in Figure 3 also (on the left), and some 
demographic and tumor information is summarized 
(middle-right to lower-right).
DISCUSSION
Here we looked at the benefit of profiling tumors 
using biomarkers to tailor clinical therapies accordingly, 
by investigating the differences in response between 
patients that followed such recommendations to those that 
did not completely adhere to them. We used clinical data 
for a colorectal adenocarcinoma cohort of patients, whose 
Table 1: Matched and unmatched groups compared against all patients
Group Patient & Tumor Information
Age Ethnicity Histology Grade Stage Survival (Days) Mortality
All patients (95) 59.9 White: 80; Black/
African American: 
10;
Asian: 2; Hawaiian/
Pacific Islander: 1;
Other/unknown: 2
Adenocarcinoma, NOS: 69;
Mucinous adenocarcinoma: 
11;
Adenocarcinoma, intestinal 
type: 9;
Adenocarcinoma in 
adenomatous polyp: 2;
Squamous cell carcinoma, 
NOS: 2;
Signet ring cell carcinoma: 1;
Tubular adenoma, NOS: 1
Grade 2 / Moderately 
differentiated: 63 (66%);
Grade 3/ Poorly differentiated: 
16 (17%);
Unknown / Not determined: 9 
(10%);
Grade 1 / Well differentiated: 
3 (3%);
Grade 4 / Undifferentiated: 2 
(2%);
None / Not applicable: 2 (2%)
IV: 38 (40%);
III no IIIC: 23 
(24%);
IIIC: 11 (12%);
II: 9 (10%);
I: 6 (6%);
Unknown: 8 (8%)
497 36%
Matched only 
(42)
60.3 White: 32; Asian: 
1; Black/African 
American: 8;
Hawaiian/Pacific 
Islander: 1;
Other/unknown: 0
Adenocarcinoma, NOS: 29;
Adenocarcinoma, intestinal 
type: 5;
Mucinous adenocarcinoma: 3;
Squamous cell carcinoma, 
NOS: 2;
Adenocarcinoma in 
adenomatous polyp: 2;
Signet ring cell carcinoma: 1
Grade 2 / Moderately 
differentiated: 29 (69%);
Unknown / Not determined: 6 
(14%);
Grade 3/ Poorly differentiated: 
4 (10%);
Grade 4 / Undifferentiated: 2 
(5%);
None / Not applicable: 1 (2%)
IV: 14 (33%);
III no IIIC: 13 
(31%);
IIIC: 3 (7%);
II: 4 (9%);
I: 4 (9%);
Unknown: 4 (9%)
442 19%
Unmatched (53) 59.5 White: 48; Black/
African American: 2;
Asian: 1; Hawaiian/
Pacific Islander: 0;
Other/unknown: 2
Adenocarcinoma, NOS: 40;
Mucinous adenocarcinoma: 8;
Adenocarcinoma, intestinal 
type: 4;
Tubular adenoma, NOS: 1
Grade 2 / Moderately 
differentiated: 34 (64%);
Grade 3/ Poorly differentiated: 
12 (22%);
Unknown / Not determined: 3 
(6%);
Grade 1 / Well differentiated: 
3 (6%);
None / Not applicable: 1 (2%)
IV: 24 (45%);
III no IIIC: 10 
(19%);
IIIC: 8 (15%);
II: 5 (9%);
I: 2 (4%);
Unknown: 4 (8%)
541 49%
Figure 1: Treatment schedules are shown in ascending post-profiling survival time for 42 matched (on the left, darker 
gray background) and 53 unmatched patients (on the right, lighter gray background). A black line at the top of a bar shows 
that the patient was deceased. Dark gray within a bar is time monitored to either death or last follow-up. Green is time on a drug of benefit. 
Red is a lack of benefit treatment. Yellow is a combination therapy composed of both benefit and lack of benefit drugs. Blue is a neutral 
therapy (neither benefit nor lack of benefit).
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Figure 2: A Volcano plot is shown denoting the biomarkers’ prognostic value. Only one biomarker of significance is found 
(on the top left), the immunohistochemistry thymidylate synthase (TS) marker. Red circle = the hazard rate of a positive biomarker result 
is significantly higher than that of a negative biomarker result, grey = the difference between a positive biomarker result and a negative 
biomarker result is not significant. Red line = significance threshold.
Figure 3: Left: biomarker statuses in the treatment groups, where the size of the circle indicates the number of cases. 
Top-right: A Kaplan-Meier curve of overall survival from time of profiling, comparing treatment groups. Middle-right to lower-right: a 
summary of patient ages, survival time, treatment numbers, and grade of samples. Blue = matched patients, red = unmatched patients.
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clinicians received treatment suggestions that used tumor 
molecular profiling by Caris Life Sciences and received 
associated treatment predictions.
The unmatched group received 6.6 more drug 
therapies than the matched group on average, and had 
a poorer survival prognosis, although these patients did 
have tumors that were more advanced than in the matched 
group, as shown in Table 2. We find that thymidylate 
synthase (TS) as an immunohistochemical marker is 
associated with significantly worse outcomes in this cohort 
(Figure 2).  
The survival curves for the different treatment 
groups overlap but then diverge. This indicates that 
therapy predictions guided by tumor profiling have a 
positive effect on the choice of therapies and leads to 
an improved outcome, as would be expected if correct 
stratification of treatments occurs in the clinic. A reduction 
in mortality was also detected giving. Overall this gives 
a good indication that there is a benefit from tumor 
molecular profiling in this colorectal adenocarcinoma 
cohort using this technology.
MATERIALS AND METHODS
The Caris CODE database (version 1.0) contains 
tumor molecular profile data for 841 patients with solid 
tumors. It also contains demographic information about 
these patients, the drug treatments that they received 
before and after molecular profiling and records of their 
clinical outcomes while they were still being monitored. 
There are 95 colorectal adenocarcinoma patients within 
this database, and this colorectal cancer cohort was mined 
after web scraping the data from the Caris CODE website, 
to understand if molecular characterization affected drug 
selection by treating physicians, and if any molecular 
subsets had different outcomes across tumor types. Table 
1 describes the clinical characteristics of the patients that 
were profiled. According to Caris Life Sciences, 36% of 
cases used here had a metastatic sample profiled.
As shown in Figure 1, the amount of time that 
patients were monitored varied, although on average 
patients’ treatment records were available for 966 days 
(733 for matched treatment patients, 1150 for unmatched 
Table 2: Most common drugs given more than once, and those that were profiled to be of benefit, 
of no benefit, or classed as neither of these
Number of 
Patients Most Frequently Administered Drugs (Total Treatment Periods)
All patients 
treated
All patients 
(95) – treatment 
periods
Matched only 
patients (42), all 
treatments
Matched, 
after profiling 
treatments only
Unmatched 
patients 
(53), all 
treatments
Unmatched, 
after profiling 
treatments only
Drugs 
predicted of 
benefit
Drugs 
predicted to 
lack benefit
Drugs with 
no prediction 
(neither of benefit 
or lack of benefit)
fluorouracil – 87 
patients
fluorouracil = 
168
fluorouracil = 47 fluorouracil = 16 fluorouracil 
= 121
fluorouracil = 49 fluorouracil 
= 115
irinotecan 
hydrochloride 
= 34
leucovorin calcium 
= 120
oxaliplatin – 81 
patients
leucovorin 
calcium = 127
oxaliplatin =36 bevacizumab = 13; 
oxaliplatin = 13
leucovorin 
calcium = 92
leucovorin 
calcium = 39
oxaliplatin  
= 46
oxaliplatin 
= 28
bevacizumab = 59
leucovorin 
calcium – 77 
patients
oxaliplatin = 109 leucovorin calcium 
= 35
- bevacizumab 
= 75
irinotecan 
hydrochloride 
= 27
bevacizumab 
= 33
fluorouracil 
= 25
oxaliplatin = 26
bevacizumab – 52 
patients
bevacizumab 
= 96
bevacizumab = 21 leucovorin calcium 
= 12
oxaliplatin = 
73
bevacizumab 
= 24
irinotecan 
hydrochloride 
= 21
cetuximab 
= 9
capecitabine = 24
irinotecan 
hydrochloride – 
47 patients
irinotecan 
hydrochloride 
= 62
capecitabine = 18 capecitabine = 9 irinotecan 
hydrochloride 
= 49
oxaliplatin = 16 capecitabine 
= 14
capecitabine 
= 5
fluorouracil = 18
capecitabine – 31 
patients
capecitabine 
= 47
irinotecan 
hydrochloride = 13
irinotecan 
hydrochloride = 7
capecitabine 
= 29
cetuximab = 13 cetuximab = 6 panitumumab 
= 3
ziv-aflibercept = 9
cetuximab – 15 
patients
cetuximab = 17 l-leucovorin = 2; 
ziv-aflibercept = 2
l-leucovorin = 2; 
ziv-aflibercept = 2
cetuximab 
= 16
capecitabine = 7 doxorubicin 
hydrochloride 
= 2
- l-leucovorin = 6
ziv-aflibercept – 8 
patients
ziv-aflibercept 
= 9
- - ziv-aflibercept 
= 7
ziv-aflibercept 
= 6
- - cyclophosphamide 
= 3
l-leucovorin; 
panitumumab – 6 
patients
l-leucovorin = 
6; panitumumab 
= 6 
- - panitumumab 
= 5
panitumumab = 
3; l-leucovorin 
n = 3
- - cetuximab = 2;
irinotecan 
hydrochloride = 2;
everolimus = 2;
placebo = 2
- - - - l-leucovorin n 
= 4
- - - -
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patients), and on average the time of monitoring after 
profiling was 497 days. The longest amount of time that 
records were available, i.e. before and after diagnosis, 
up until the last contact day, was 4442 days. The longest 
period of monitoring after tumor profiling (the patient 
represented on the furthest right of Figure 1) was 1594 
days; this was 1634 days after diagnosis. 
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